At ObesityWeek, Novo Nordisk (NVO) presented new post hoc analyses from the phase 3 REDEFINE 1 trial evaluating CagriSema, an investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results